Trans-Cinnamic acid
Based on 3 publication(s) in Google Scholar
trans-Cinnamic acid is a natural antimicrobial, with minimal inhibitory concentration (MIC) of 250 μg/mL against fish pathogen A. sobria, SY-AS1.
For research use only. We do not sell to patients.
- Purity: 99.89%
- CAS No.: 140-10-3
- Formula: C9H8O2
- Molecular Weight:148.16
-
Storage:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Trans-Cinnamic acid
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
Microbial Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
64 μM
Compound: 16a
|
Anticancer activity against human A375 cells after 48 hrs by MTT assay
Anticancer activity against human A375 cells after 48 hrs by MTT assay
|
[PMID: 22136907] |
| A549 | IC50 |
3.54 mM
Compound: Cinnamic acid
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 31336310] |
| A549 | IC50 |
50.18 μM
Compound: CA
|
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
10.1039/C6MD00178E |
| A549 | IC50 |
87 μM
Compound: 16a
|
Anticancer activity against human A549 cells after 48 hrs by MTT assay
Anticancer activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 22136907] |
| ACHN | IC50 |
91 μM
Compound: 16a
|
Anticancer activity against human ACHN cells after 48 hrs by MTT assay
Anticancer activity against human ACHN cells after 48 hrs by MTT assay
|
[PMID: 22136907] |
| BALB/3T3 | IC50 |
671.4 μM
Compound: 11
|
Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay
Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay
|
[PMID: 10096863] |
| BMDM | IC50 |
>100 μM
Compound: trans-cinnamic acid
|
Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base
Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base
|
[PMID: 31257875] |
| BV-2 | EC50 |
>10 μM
Compound: CA
|
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay
|
[PMID: 29407994] |
| BV-2 | IC50 |
>100 μM
Compound: 22
|
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay
|
[PMID: 28911817] |
| DLD-1 | IC50 |
0.685 μM
Compound: 25, IWR-1
|
Inhibition of tankyrase in human DLD1 cells assessed as reduction in Wnt activity after 24 hrs by TCF-luciferase reporter gene assay
Inhibition of tankyrase in human DLD1 cells assessed as reduction in Wnt activity after 24 hrs by TCF-luciferase reporter gene assay
|
[PMID: 25299683] |
| HeLa | IC50 |
24.81 μM
Compound: CA
|
Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
10.1039/C6MD00178E |
| HT-144 | IC50 |
1.07 mM
Compound: Cinnamic acid
|
Cytotoxicity against human HT144 cells after 48 hrs by MTT assay
Cytotoxicity against human HT144 cells after 48 hrs by MTT assay
|
[PMID: 31336310] |
| HT-144 | IC50 |
2.4 mM
Compound: Cinnamic acid
|
Cytotoxicity against human HT144 cells after 24 hrs by MTT assay
Cytotoxicity against human HT144 cells after 24 hrs by MTT assay
|
[PMID: 31336310] |
| HT-22 | EC50 |
>10 μM
Compound: CA
|
Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay
Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay
|
[PMID: 29407994] |
| HT-29 | IC50 |
114 μM
Compound: 16a
|
Anticancer activity against human HT-29 cells after 48 hrs by MTT assay
Anticancer activity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 22136907] |
| MCF7 | IC50 |
108 μM
Compound: 16a
|
Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 22136907] |
| MIA PaCa-2 | IC50 |
1.33 mM
Compound: Cinnamic acid
|
Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay
|
[PMID: 31336310] |
| NCI-H460 | IC50 |
2.1 mM
Compound: Cinnamic acid
|
Cytotoxicity against human H460 cells after 48 hrs by MTT assay
Cytotoxicity against human H460 cells after 48 hrs by MTT assay
|
[PMID: 31336310] |
| Oocyte | IC50 |
34.6 μM
Compound: Cin-COOH
|
Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique
Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique
|
[PMID: 23682762] |
| RAW264.7 | GI50 |
6547 μM
Compound: 1d
|
Cytotoxicity against mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by trypan blue assay
Cytotoxicity against mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by trypan blue assay
|
10.1039/C3MD00251A |
trans-Cinnamic acid is an antimicrobial activity, with minimal inhibitory concentration (MIC) of 250 μg/mL against fish pathogen A. sobria, SY-AS1. trans-cinnamic acid shows moderate inhibition on the rainbow trout intestinal isolates A. sobria SY-AS3 and S. baltica, SY-S145, gill isolate F. spartansii SY-FS1 and fish pathogens A. salmonicida ATCC 33658, Listonella anguillarum, SY-L24, V. crassostreae SY-VC10 and Y. ruckeri E42. trans-cinnamic acid is more effective on bacteria when the pH of the culture media is not neutralized[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 140-10-3
-
Appearance Solid
-
Molecular Weight 148.16
-
Formula C9H8O2
-
Color White to off-white
-
SMILES
O=C(O)/C=C/C1=CC=CC=C1
-
Synonyms
Trans-3-Phenylacrylic acid
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
J Nutr Biochem
Trans-cinnamic acid alleviates high-fat diet-induced renal injury via JNK/ERK/P38 MAPK pathway. [Abstract]2024 Sep 12:109769. PMID: 39276944 -
Biochim Biophys Acta Mol Cell Biol Lipids
trans-Cinnamic acid alleviates high-fat diet induced hepatic steatosis by activating AMPK-mTOR pathway. [Abstract]2026 May;1871(4):159741. PMID: 41932676 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607
Solvent & Solubility
DMSO : 100 mg/mL (674.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (16.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (16.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.7495 mL | 33.7473 mL | 67.4946 mL | 168.7365 mL |
| 5 mM | 1.3499 mL | 6.7495 mL | 13.4989 mL | 33.7473 mL | |
| 10 mM | 0.6749 mL | 3.3747 mL | 6.7495 mL | 16.8736 mL | |
| 15 mM | 0.4500 mL | 2.2498 mL | 4.4996 mL | 11.2491 mL | |
| 20 mM | 0.3375 mL | 1.6874 mL | 3.3747 mL | 8.4368 mL | |
| 25 mM | 0.2700 mL | 1.3499 mL | 2.6998 mL | 6.7495 mL | |
| 30 mM | 0.2250 mL | 1.1249 mL | 2.2498 mL | 5.6245 mL | |
| 40 mM | 0.1687 mL | 0.8437 mL | 1.6874 mL | 4.2184 mL | |
| 50 mM | 0.1350 mL | 0.6749 mL | 1.3499 mL | 3.3747 mL | |
| 60 mM | 0.1125 mL | 0.5625 mL | 1.1249 mL | 2.8123 mL | |
| 80 mM | 0.0844 mL | 0.4218 mL | 0.8437 mL | 2.1092 mL | |
| 100 mM | 0.0675 mL | 0.3375 mL | 0.6749 mL | 1.6874 mL |